New mRNA HIV vaccines enter human testing
NCT ID NCT07390474
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests two experimental mRNA vaccines designed to train the immune system to make special antibodies that could block HIV. The study involves 40 healthy adults without HIV who will receive the vaccines and be monitored for safety and immune responses. It is the first time these vaccines are being tested in humans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA vaccines (DV201P-RNA and DV202B1-RNA) designed to train the immune system to produce HIV-fighting antibodies
What this could lead to
If successful, this could point toward a vaccine that helps prevent HIV infection by teaching the body to make powerful antibodies.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not effectiveness. The vaccines may not trigger the desired immune response or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center VCRS (BIDMC VCRS Site # 32077)
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Columbia P&S CRS (Site ID: 30329)
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Penn Prevention CRS
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Hope Clinic of the Emory Vaccine Research Center; Emory University
RECRUITINGDecatur, Georgia, 30030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Ponce de Leon Center CRS
NOT_YET_RECRUITINGAtlanta, Georgia, 30308, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh CRS
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Rochester Vaccines to Prevent HIV Infection CRS
NOT_YET_RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••